GHRL and dementia: Considering that Aβ deposits in the neocortex represent the first of the five phases of Aβ deposition and the patients with AD in the early phase of Aβ deposition do not exhibit dementia [63], our data indicated that the administration of a ghrelin agonist in the early stage of AD could alleviate Aβ accumulation before the onset of AD-related symptoms.